Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study)
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ..
INTRODUCTION: Scabies is a significant contributor to global morbidity, affecting approximately 200 million people at any time. Scabies is endemic in many resource-limited tropical settings. Bacterial skin infection (impetigo) frequently complicates scabies infestation in these settings. Community-wide ivermectin-based mass drug administration (MDA) is an effective control strategy for scabies in island settings, with a single round of MDA reducing population prevalence by around 90%. However, current two-dose regimens present a number of barriers to programmatic MDA implementation. We designed the Regimens of Ivermectin for Scabies Elimination (RISE) trial to investigate whether one-dose MDA may be as effective as two-dose MDA in controlling scabies in high-prevalence settings.
METHODS AND ANALYSIS: RISE is a cluster-randomised non-inferiority trial. The study will be conducted in 20 isolated villages in Western Province of Solomon Islands where population prevalence of scabies is approximately 20%. Villages will be randomly allocated to receive either one dose or two doses of ivermectin-based MDA in a 1:1 ratio. The primary objective of the study is to determine if ivermectin-based MDA with one dose is as effective as MDA with two doses in reducing the prevalence of scabies after 12 months. Secondary objectives include the effect of ivermectin-based MDA on impetigo prevalence after 12 and 24 months, the prevalence of scabies at 24 months after the intervention, the impact on presentation to health facilities with scabies and impetigo, and the safety of one-dose and two-dose MDA.
ETHICS AND DISSEMINATION: This trial has been approved by the ethics review committees of the Solomon Islands and the Royal Children's Hospital, Australia. Results will be disseminated in peer-reviewed publications and in meetings with the Solomon Islands Ministry of Health and Medical Services and participating communities.
TRIAL REGISTRATION DETAILS: Australian New Zealand Clinical Trials Registry: ACTRN12618001086257. Date registered: 28 June 2018.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
BMJ open - 10(2020), 8 vom: 30. Aug., Seite e037305 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lake, Susanna J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
70288-86-7 |
|---|
| Anmerkungen: |
Date Completed 18.03.2021 Date Revised 18.03.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2020-037305 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314414606 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314414606 | ||
| 003 | DE-627 | ||
| 005 | 20231226201839.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2020-037305 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1048.xml |
| 035 | |a (DE-627)NLM314414606 | ||
| 035 | |a (NLM)32868360 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lake, Susanna J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2021 | ||
| 500 | |a Date Revised 18.03.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. | ||
| 520 | |a INTRODUCTION: Scabies is a significant contributor to global morbidity, affecting approximately 200 million people at any time. Scabies is endemic in many resource-limited tropical settings. Bacterial skin infection (impetigo) frequently complicates scabies infestation in these settings. Community-wide ivermectin-based mass drug administration (MDA) is an effective control strategy for scabies in island settings, with a single round of MDA reducing population prevalence by around 90%. However, current two-dose regimens present a number of barriers to programmatic MDA implementation. We designed the Regimens of Ivermectin for Scabies Elimination (RISE) trial to investigate whether one-dose MDA may be as effective as two-dose MDA in controlling scabies in high-prevalence settings | ||
| 520 | |a METHODS AND ANALYSIS: RISE is a cluster-randomised non-inferiority trial. The study will be conducted in 20 isolated villages in Western Province of Solomon Islands where population prevalence of scabies is approximately 20%. Villages will be randomly allocated to receive either one dose or two doses of ivermectin-based MDA in a 1:1 ratio. The primary objective of the study is to determine if ivermectin-based MDA with one dose is as effective as MDA with two doses in reducing the prevalence of scabies after 12 months. Secondary objectives include the effect of ivermectin-based MDA on impetigo prevalence after 12 and 24 months, the prevalence of scabies at 24 months after the intervention, the impact on presentation to health facilities with scabies and impetigo, and the safety of one-dose and two-dose MDA | ||
| 520 | |a ETHICS AND DISSEMINATION: This trial has been approved by the ethics review committees of the Solomon Islands and the Royal Children's Hospital, Australia. Results will be disseminated in peer-reviewed publications and in meetings with the Solomon Islands Ministry of Health and Medical Services and participating communities | ||
| 520 | |a TRIAL REGISTRATION DETAILS: Australian New Zealand Clinical Trials Registry: ACTRN12618001086257. Date registered: 28 June 2018 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a dermatology | |
| 650 | 4 | |a infectious diseases | |
| 650 | 4 | |a international health services | |
| 650 | 4 | |a tropical medicine | |
| 650 | 7 | |a Antiparasitic Agents |2 NLM | |
| 650 | 7 | |a Ivermectin |2 NLM | |
| 650 | 7 | |a 70288-86-7 |2 NLM | |
| 700 | 1 | |a Phelan, Sophie L |e verfasserin |4 aut | |
| 700 | 1 | |a Engelman, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Sokana, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Nasi, Titus |e verfasserin |4 aut | |
| 700 | 1 | |a Boara, Dickson |e verfasserin |4 aut | |
| 700 | 1 | |a Gorae, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Schuster, Tibor |e verfasserin |4 aut | |
| 700 | 1 | |a Grobler, Anneke C |e verfasserin |4 aut | |
| 700 | 1 | |a Osti, Millicent H |e verfasserin |4 aut | |
| 700 | 1 | |a Andrews, Ross |e verfasserin |4 aut | |
| 700 | 1 | |a Marks, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Whitfeld, Margot J |e verfasserin |4 aut | |
| 700 | 1 | |a Romani, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Kaldor, John |e verfasserin |4 aut | |
| 700 | 1 | |a Steer, Andrew |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 10(2020), 8 vom: 30. Aug., Seite e037305 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:8 |g day:30 |g month:08 |g pages:e037305 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2020-037305 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 8 |b 30 |c 08 |h e037305 | ||